Abstract
Tumor neoantigen peptides or tumor specific antigens (TSA) offer new possibilities in cancer immunotherapy. These peptides which are found exclusively on tumor cells make them ideal targets for personalized medicine as anti-cancer vaccines or for ex vivo cell therapy. This introduces the need for rapid synthesis of multiple peptides manufactured and released under GMP conditions.
This white paper is a journey through the new developments in neoantigen research. It will guide you through the origins of neoantigens, explain the detailed steps of the immune response to these neoantigens, provide examples of how neoantigens are utilized in cancer vaccines and ex vivo therapies. The paper will also describe how to overcome the negative impact of check point inhibitors, demonstrate the achievements in neoantigen immunotherapy, and reveal new goals in personalized medicine.
